Dextromethorphan and guaifenesin use needs to be monitored cautiously in clients with "very poor metabolizer" CYP2D6 enzyme levels and people who are sedated. This combination medication provides a massive median poisonous dose (TD50) to median successful dose (ED50) ratio (or therapeutic index) in these sufferers.When you've got questions about